TIMP2 and sarcoma: In addition, MT1-MMP induces epithelial–mesenchymaltransition, a process by which cancer cells undergo changes in theirmorphology, leading to a migratory phenotype,16 promoting extravasation into adjacent blood vessels and metastasisto distant tissues.17 Lastly, MT1-MMP bindingto the tissue inhibitor of metalloproteinases 2 (TIMP-2) increasesexpression of MMP-2, which is associated with a poor response to chemotherapyin some bone sarcoma subtypes.18 MT1-MMPtherefore represents an attractive imaging biomarker of sarcomas.